GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Bioequivalence Study for an Isotretinoin
- First Posted Date
- 2013-05-29
- Last Posted Date
- 2017-07-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 36
- Registration Number
- NCT01863615
- Locations
- 🇲🇽
GSK Investigational Site, Monterrey, Nuevo León, Mexico
Bioequivalence Study of Montelukast 5 mg Chewable
- First Posted Date
- 2013-05-29
- Last Posted Date
- 2017-06-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 32
- Registration Number
- NCT01863654
Drug Use Investigation for HEPSERA (Adefovir) Tablet
- First Posted Date
- 2013-05-29
- Last Posted Date
- 2013-05-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 436
- Registration Number
- NCT01863589
Special Drug Use Investigation for LAMICTAL® (Long Term)
- First Posted Date
- 2013-05-29
- Last Posted Date
- 2016-11-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 850
- Registration Number
- NCT01863602
Single Oral Dose Study of Atovaquone/Proguanil Hydrochloride Combination Tablets and Atovaquone Suspension
- First Posted Date
- 2013-05-21
- Last Posted Date
- 2017-03-22
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 30
- Registration Number
- NCT01858831
- Locations
- 🇯🇵
GSK Investigational Site, Kagoshima, Japan
Feasibility Study of Exenatide by Continuous Subcutaneous Infusion
- First Posted Date
- 2013-05-20
- Last Posted Date
- 2017-10-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 10
- Registration Number
- NCT01857895
- Locations
- 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States
Efficacy, Safety and Immunogenicity Study of GlaxoSmithKline(GSK) Biologicals' Candidate Malaria Vaccine 257049 in the Sporozoite Challenge Model in Healthy Malaria-naïve Adults
Phase 2
Completed
- Conditions
- Malaria
- Interventions
- Biological: GSK257049 Dosage 1Procedure: Sporozoite-infected mosquitoes challengeBiological: GSK257049 Dosage 2
- First Posted Date
- 2013-05-20
- Last Posted Date
- 2019-06-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 64
- Registration Number
- NCT01857869
- Locations
- 🇺🇸
GSK Investigational Site, Silver Spring, Maryland, United States
Safety and Efficacy Study of GR68755 (Alosetron Hydrochloride) to Treat Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS)
Phase 2
Completed
- Conditions
- Irritable Colon
- Interventions
- Drug: GR68755 (Alosetron hydrochloride) 1 mg tablet
- First Posted Date
- 2013-05-16
- Last Posted Date
- 2017-05-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 32
- Registration Number
- NCT01855711
Bioequivalence Trial of Alprazolam 0.25 mg Tablets
- First Posted Date
- 2013-05-15
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 28
- Registration Number
- NCT01853956
A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor
Phase 2
Completed
- Conditions
- Lung Cancer, Non-Small Cell
- Interventions
- Biological: Recombinant PRAME protein combined with the AS15 Adjuvant System GSK2302032ABiological: Placebo
- First Posted Date
- 2013-05-15
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 137
- Registration Number
- NCT01853878
- Locations
- 🇬🇧
GSK Investigational Site, Sheffield, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath